Fabtech Technologies FY26 revenue rises 28% to Rs 431 crore

Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets

Our hybrid model combines global manufacturing with local clinical scale: Kavinder Beniwal, Chief Operational Officer, Motorica India

With the convergence of AI, robotics, and neuroscience, Motorica is advancing toward more intuitive, intent-driven prosthetic systems

Syngene reports FY26 revenue of Rs 3,739 Cr, up 3%; Q4 revenue at Rs 1,037 Cr

Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities

Monitra Health raises fresh funding to scale upBeat® cardiac monitoring platform globally

The medtech firm strengthens its full-stack remote cardiac monitoring platform, achieves 11x revenue growth, and advances its global expansion plans

Ferrotec launches fast & flexible DNA/RNA isolation kit aimed at streamlining lab workflows

Cubo set to transform decentralised diagnostics with Compact RT-PCR innovation

Avio Smart Market Stack Limited and Huwel Lifesciences unveil portable, cost-efficient molecular testing platform

FDA okays AstraZeneca’s triple therapy Breztri for asthma

The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device

The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings

With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints

Sun Pharma eyes biosimilars-led growth, Organon deal to build $12.4 billion global platform

On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms

Biosimilars gain momentum as US market sees 92 approvals: Samsung Bioepis report

Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation